MannKind (MNKD) to Release Quarterly Earnings on Wednesday

MannKind (NASDAQ:MNKD) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $58.47 million for the quarter, compared to analyst estimates of $52.36 million. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Stock Up 2.1 %

Shares of MannKind stock traded up $0.09 during trading on Monday, hitting $4.48. 282,110 shares of the stock traded hands, compared to its average volume of 2,859,315. MannKind has a twelve month low of $3.17 and a twelve month high of $5.75. The company has a fifty day moving average price of $4.42 and a two-hundred day moving average price of $3.92.

Analyst Upgrades and Downgrades

MNKD has been the subject of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $10.00 price target on shares of MannKind in a research report on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $6.50 target price on shares of MannKind in a research report on Friday, March 15th.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.